Non-HDL-c/TC: A Novel Lipid-Related Marker in the Assessment of Severity of Coronary Artery Lesions and Cardiovascular Outcomes

Table 3

Baseline characteristics of CAD patients with adverse and nonadverse events.

	Nonadverse events (n = 317)	Adverse events (n = 55)	value
Age (years)	62.79 ± 8.12	63.06 ± 7.97	0.827
Male (n (%))	177 (55.8%)	24 (43.6%)	0.093
Smoking (n (%))	143 (45.1%)	35 (63.6%)	0.011
Medical history (n (%))
Hypertension	190 (59.9%)	24 (43.6%)	0.024
DM	128 (40.4%)	30 (54.5%)	0.050
Dyslipidemia	181 (57.1%)	31 (56.4%)	0.919
Laboratory index
CK (U/L)	81 (57, 126)	72 (51, 155)	0.993
CK-MB (U/L)	12 (9, 16)	11 (8, 17)	0.964
hs-CRP (mg/L)	1.70 (0.67, 3.27)	1.38 (0.66, 5.17)	0.760
Cr (mg/dL)	0.71 (0.62, 0.87)	0.72 (0.62, 0.85)	0.687
HbA1c (%)	6.1 (5.7, 6.8)	6.3 (5.8, 7.3)	0.063
TC (mg/dL)	175.70 (157.90, 202.01)	181.50 (144.74, 200.85)	0.947
TG (mg/dL)	138.94 (102.66, 184.97)	147.80 (105.32, 181.43)	0.896
HDL-c (mg/dL)	45.67 (39.86, 53.79)	41.80 (37.93, 46.83)	0.011
LDL-c (mg/dL)	114.55 ± 31.35	112.62 ± 27.86	0.684
VLDL-c (mg/dL)	27.48 (20.51, 37.93)	27.09 (20.90, 35.22)	0.792
LVEF (%)	58 (57, 61)	58 (56, 60)	0.054
Gensini score	26 (10, 50)	64 (33, 104)	<0.001
Non-LDL-c (mg/dL)	132.47 ± 32.40	133.80 ± 33.07	0.785
Non-LDL-c/TC	0.74 (0.70, 0.78)	0.77 (0.72, 0.78)	0.031

Values are mean ± SD (standard deviation), median (percentiles 25th–75th), or n (%). value indicates comparison between nonadverse events and adverse events subgroup. DM: diabetes mellitus; CK: creatinine kinase; CK-MB: creatinine kinase-MB; hs-CRP: high-sensitivity C-reactive protein; Cr: creatinine; HbA1c: hemoglobin A1c; TC: total cholesterol; TG: total triglyceride; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol; VLDL-c: very-low-density lipoprotein cholesterol; LVEF: left ventricular ejection fraction.